VLS-1488 is under clinical development by Volastra Therapeutics and currently in Phase II for Esophageal Squamous Cell Carcinoma (ESCC). According to GlobalData, Phase II drugs for Esophageal Squamous Cell Carcinoma (ESCC) have a 56% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how VLS-1488’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

VLS-1488 overview

VLS-1488 is under development for the treatment of solid tumors like ovarian cancer, squamous non -small cell lung cancer, triple negative breast cancer, gastric adenocarcinoma, colorectal cancer, esophageal squamous cell carcinoma, esophageal adenocarcinoma, gastroesophageal junction carcinoma, bladder (transitional cell) cancer, head and neck squamous cell carcinomas, ovarian carcinosarcoma, cn-high endometrial/uterine cancer. It is a chromosomal instability (CIN)-related synthetic lethal drug acts by targeting KIF18A and is being developed based on CINtech platform. It is administered through oral route.

Volastra Therapeutics overview

Volastra Therapeutics discovers and develops drugs for oncology indications. The company is investigating K1F18A, a mitotic kinesin; and CRISPR hits programs to find synthetic lethal targets. Volastra Therapeutics utilizes its proprietary CINtech (chromosomal instability technology) platform to identify and create drugs for cancer. The company works in partnership with Weill Cornell Medicine, Dewpoint Therapeutics Inc, and other companies to advance its science and create cancer therapies. It operates across the US. Volastra Therapeutics is headquartered in New York city, New York, the US.

For a complete picture of VLS-1488’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.